Patents by Inventor Carolin Hoft
Carolin Hoft has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200283439Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: ApplicationFiled: October 14, 2019Publication date: September 10, 2020Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
-
Publication number: 20200039930Abstract: The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of the 5-HT2C receptor, and processes for preparing such compounds and compositions.Type: ApplicationFiled: March 20, 2018Publication date: February 6, 2020Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Lawrence Black, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Carolin Hoft, Andreas Kling, Viktor Lakics, Helmut Mack, Frank Oellien, Ana Lucia Relo
-
Publication number: 20200002354Abstract: The present invention relates to compound of formula (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: ApplicationFiled: September 3, 2019Publication date: January 2, 2020Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Günter Blaich, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Carolin Hoft, Viktor Lakics, Helmut Mack, Frank Oellien, Raimund Peter, Ana Lucia Relo
-
Publication number: 20190071443Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: ApplicationFiled: November 2, 2018Publication date: March 7, 2019Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
-
Publication number: 20190062305Abstract: The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl-bound N-amide moiety derived from an ?-amino acid of formula I where the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, and to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT2C receptor.Type: ApplicationFiled: September 21, 2016Publication date: February 28, 2019Inventors: Gisela BACKFISCH, Margaretha BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Carolin HOFT, Andreas KLING, Viktor LAKICS, Helmut MACK, Frank OELLIEN, Raimund PETER, Frauke POHLKI, Ana Lucia RELO
-
Publication number: 20190048007Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: ApplicationFiled: June 8, 2018Publication date: February 14, 2019Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
-
Publication number: 20180339996Abstract: The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: ApplicationFiled: November 24, 2016Publication date: November 29, 2018Inventors: Gisela BACKFISCH, Margaretha Henrica Maria BAKKER, Günter BLAICH, Wilfried BRAJE, Karla DRESCHER, Thomas ERHARD, Andreas HAUPT, Carolin HOFT, Viktor LAKICS, Helmut MACK, Frank OELLIEN, Raimund PETER, Ana Lucia RELO
-
Patent number: 10118926Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: GrantFiled: September 13, 2013Date of Patent: November 6, 2018Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
-
Patent number: 9994568Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: GrantFiled: September 29, 2015Date of Patent: June 12, 2018Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KGInventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
-
Patent number: 9540370Abstract: The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3?, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3? activity using the compounds.Type: GrantFiled: June 15, 2015Date of Patent: January 10, 2017Assignee: ABBVIE DEUTSCHLAND GMBH & CO., KG.Inventors: Sean Colm Turner, Helmut Mack, Margaretha Henrica Maria Bakker, Marcel van Gaalen, Carolin Hoft, Wilfried Hornberger
-
Publication number: 20160016954Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: ApplicationFiled: September 29, 2015Publication date: January 21, 2016Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
-
Patent number: 9169253Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: GrantFiled: March 15, 2013Date of Patent: October 27, 2015Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margaretha Henrica Maria Bakker, Viktor Lakics, Carolin Hoft
-
Publication number: 20150274724Abstract: The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3?, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3? activity using the compounds.Type: ApplicationFiled: June 15, 2015Publication date: October 1, 2015Inventors: Sean Colm Turner, Helmut Mack, Margaretha Henrica Maria Bakker, Marcel van Gaalen, Carolin Hoft, Wilfried Hornberger
-
Patent number: 9090592Abstract: The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3?, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3? activity using the compounds.Type: GrantFiled: December 29, 2011Date of Patent: July 28, 2015Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Sean Colm Turner, Helmut Mack, Margaretha Henrica Maria Bakker, Marcel Van Gaalen, Carolin Hoft, Wilfried Hornberger
-
Publication number: 20140080816Abstract: The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.Type: ApplicationFiled: September 13, 2013Publication date: March 20, 2014Inventors: Hannes Koolman, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana Lucia Relo, Karla Drescher, Margot Bakker, Viktor Lakics, Carolin Hoft, Ruxu Xu, Xiaona Zhao
-
Publication number: 20120172376Abstract: The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3?, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3? activity using the compounds.Type: ApplicationFiled: December 29, 2011Publication date: July 5, 2012Applicant: Abbott GmbH & Co. KGInventors: Sean Colm Turner, Helmut Mack, Margaretha Henrica Maria Bakker, Marcel van Gaalen, Carolin Hoft, Wilfried Hornberger